Advancing treatments for rare diseases together

EspeRare's CEO in the spotlight in Biotech Finance

27Feb

For its issue "Special rare diseases", the journal Biotech Finances has chosen to feature EspeRare's CEO, Caroline Kant.The interview summarises Caroline Kant's career path as well as EspeRare's aims, realizations and business plan, thereby informing finance and biotechs specialists of EspeRare's unique business model.

http://www.eei-biotechfinances.com/